A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Trial details
- Registry ID
- NCT05531656
- Drugs studied
- CT1812
TrialRedline tracks 5 clinical trials sponsored by Cognition Therapeutics: 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 | CT1812 | Active not recruiting | 2027-05-31Estimated |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415 | CT1812 | Completed | 2024-11-25Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790 | CT1812 | Completed | 2024-05-29Actual |
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536 | CT1812 | Completed | 2023-04-26Actual |
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).NCT05893537 | Active Comparator CT1812 | Terminated | 2025-03-04Actual |
Names as written in the registry records.
NCT05531656 · Cognition Therapeutics
Before: Apr 2027. After: 31 May 2027.
NCT05225415 · Cognition Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and Tolerability of CT1812. After: Measure: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs).